Evaluation of the protection against myxomatosis and viral haemorrhagic disease of rabbit conferred by a bivalent vaccine administered intradermally
De FOUCAULD J., FOURNIER D.
A group of rabbits was vaccinated intradermally at 4 weeks of age with a homologous SG33 strain myxomatosis vaccine and at 10 weeks of age with a bivalent vaccine containing the ""myxomatosis"" (SG33 strain) attenuated component and the ""rabbit haemorrhagic disease"" (VHD) component. Some of the vaccinated rabbits, along with unvaccinated control rabbits, were challenged with a virulent myxomatosis virus, approximately 4 months after vaccination with the bivalent vaccine. All the control rabbits developped myxomatosis within 4 days. None of the vaccinated animals were affected with the disease. One year after vaccination with the bivalent vaccine, all the remaining vaccinated rabbits along with control rabbits, were challenged with a virulent VHD virus. Eight out often control rabbits and one out oftwelve vaccinated animais died. As a result of these preliminary trials we can envisage a vaccination schedule for breeding animals which includes a bivalent vaccine against viral haemorrhagic disease of rabbits and myxomatosis, being given intradermally.
Scientific Literature & Other Materials
Want to dig deeper? Browse published research on a range of poultry diseases and products, plus our equipment brochures, website articles, and more.
Product background info, vaccination equipment demos, and customer testimonials—explore all these and others from our video collection.